<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254344</url>
  </required_header>
  <id_info>
    <org_study_id>0826-056</org_study_id>
    <nct_id>NCT01254344</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery in Chinese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ertapenem sodium compared
      with ceftriaxone sodium/metronidazole for the prophylaxis of surgical site infection
      following elective colorectal surgery in Chinese adults. This study is designed to
      demonstrate that ertapenem sodium is non-inferior to ceftriaxone sodium/metronidazole in this
      participant population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Success of Prophylaxis</measure>
    <time_frame>From study drug dose (day of surgery) up to 4 weeks post therapy</time_frame>
    <description>Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Favorable Clinical Response</measure>
    <time_frame>4 weeks posttreatment</time_frame>
    <description>Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">599</enrollment>
  <condition>Infection</condition>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Ertapenem sodium 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone sodium 2 g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ertapenem sodium</intervention_name>
    <description>Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision</description>
    <arm_group_label>Ertapenem sodium 1 g</arm_group_label>
    <other_name>MK-0826</other_name>
    <other_name>INVANZ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone sodium</intervention_name>
    <description>Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision</description>
    <arm_group_label>Ceftriaxone sodium 2 g</arm_group_label>
    <other_name>Rocephin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to metronidazole</intervention_name>
    <description>Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision</description>
    <arm_group_label>Ertapenem sodium 1 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <description>Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision</description>
    <arm_group_label>Ceftriaxone sodium 2 g</arm_group_label>
    <other_name>Flagyl®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Participant is scheduled to undergo elective colon or colorectal surgery by

        laparotomy that is scheduled in advance with adequate time prior to surgery to

        complete preoperative bowel preparation.

        - Participant is a Chinese adult between the ages of more than 18 years old and

        less than 81 years old.

        - Participant is highly unlikely to conceive.

        Exclusion Criteria:

          -  Participant is undergoing emergency colon or colorectal surgery.

          -  Participant requires a second planned colorectal surgery or other surgery requiring
             antibiotic prophylaxis within the 4-week follow-up period.

          -  Participant is undergoing laparoscopic-assisted surgery.

          -  Participant is undergoing an isolated rectal procedure.

          -  Participant has a decompensated intestinal obstruction.

          -  Participant has active inflammatory bowel disease involving the colon (i.e.,

        ulcerative colitis or Crohn's disease).

          -  Participant is scheduled to undergo an elective colorectal procedure for revision of a
             previous operation involving a large bowel resection.

          -  Participant has a bacterial infection at the time of surgery.

          -  Participant requires or is anticipated to need the administration of other (nonstudy
             therapy) systemic antimicrobial therapy within 1 week prior to surgery or at any time
             during this study.

          -  Participant is anticipated to receive either antibiotic or antiseptic peritoneal
             lavage during the surgery.

          -  Participant has a history of serious allergy, hypersensitivity (e.g., anaphylaxis), or
             any serious reaction to ertapenem sodium, ceftriaxone sodium, metronidazole,
             penicillin, or any cephalosporin, beta(β)-lactam, or nitroimidazole agents.

          -  Participant is breast feeding or plans to breast feed prior to the completion of the
             study period.

          -  Participant has neutropenia.

          -  Participant with immunosuppression due to an underlying disease, chronic

        immunosuppressive therapy, or use of high-dose corticosteroids.

          -  Participant has a rapidly progressive or terminal illness.

          -  Participant is considered unlikely to survive through the expected 4-week study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <results_reference>
    <citation>Leng XS, Zhao YJ, Qiu HZ, Cao YK, Zhu WH, Shen JF, Paschke A, Dai WM, Caldwell N, Wang J. Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study. J Antimicrob Chemother. 2014 Dec;69(12):3379-86. doi: 10.1093/jac/dku302. Epub 2014 Aug 23.</citation>
    <PMID>25151205</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <results_first_submitted>October 16, 2012</results_first_submitted>
  <results_first_submitted_qc>October 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2012</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ertapenem</title>
          <description>Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose</description>
        </group>
        <group group_id="P2">
          <title>Ceftriaxone/Metronidazole</title>
          <description>Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="297"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ertapenem</title>
          <description>Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose</description>
        </group>
        <group group_id="B2">
          <title>Ceftriaxone/Metronidazole</title>
          <description>Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="290"/>
            <count group_id="B2" value="297"/>
            <count group_id="B3" value="587"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="11.4"/>
                    <measurement group_id="B2" value="59.1" spread="12.1"/>
                    <measurement group_id="B3" value="59.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Success of Prophylaxis</title>
        <description>Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy</description>
        <time_frame>From study drug dose (day of surgery) up to 4 weeks post therapy</time_frame>
        <population>Primary analysis results are for &quot;evaluable-patients-only&quot;, defined as patients who received a complete dose of prophylaxis, underwent elective colorectal surgery with completion of bowel preparation procedure, had primary skin closure of the wound, and did not receive any prohibited systemic antibiotics or other prohibited anti-infective agents.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertapenem</title>
            <description>Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose</description>
          </group>
          <group group_id="O2">
            <title>Ceftriaxone/Metronidazole</title>
            <description>Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Success of Prophylaxis</title>
          <description>Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy</description>
          <population>Primary analysis results are for &quot;evaluable-patients-only&quot;, defined as patients who received a complete dose of prophylaxis, underwent elective colorectal surgery with completion of bowel preparation procedure, had primary skin closure of the wound, and did not receive any prohibited systemic antibiotics or other prohibited anti-infective agents.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" lower_limit="86.8" upper_limit="94.1"/>
                    <measurement group_id="O2" value="90.3" lower_limit="86.6" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assuming a 70% rate (i.e., proportion of participants with &quot;success of prophylaxis&quot;) for both groups and a significance level of 0.025, at least 200 evaluable participants per group were needed to have 90% probability that the lower limit of the 95% (two-sided) confidence interval for the difference in the response rates between the 2 groups was greater than -15 percentage points.</non_inferiority_desc>
            <param_type>Difference in percentage of prophylaxis</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Favorable Clinical Response</title>
        <description>Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection</description>
        <time_frame>4 weeks posttreatment</time_frame>
        <population>Population analyzed was participants who had no signs or symptoms of infection at the surgical site and did not require surgical intervention for infection.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertapenem</title>
            <description>Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose</description>
          </group>
          <group group_id="O2">
            <title>Ceftriaxone/Metronidazole</title>
            <description>Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Favorable Clinical Response</title>
          <description>Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection</description>
          <population>Population analyzed was participants who had no signs or symptoms of infection at the surgical site and did not require surgical intervention for infection.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="94.6" upper_limit="99.0"/>
                    <measurement group_id="O2" value="95.5" lower_limit="93.0" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage of prophylaxis</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to and including 28 days after last administration of study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ertapenem</title>
          <description>Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose</description>
        </group>
        <group group_id="E2">
          <title>Ceftriaxone/Metronidazole</title>
          <description>Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Incision Site Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Pelvic Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal Wound Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Anastomotic Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Anastomotic Leak</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vocal Cord Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism Venous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naimi Missoum</name_or_title>
      <organization>Merck Sharp &amp; Dohme (China) Ltd.</organization>
      <phone>+8621 2211 8546</phone>
      <email>naimi_missoum@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

